Literature DB >> 20418096

The biology and treatment of EML4-ALK non-small cell lung cancer.

Takaaki Sasaki1, Scott J Rodig, Lucian R Chirieac, Pasi A Jänne.   

Abstract

The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLCs). EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features. EML4-ALK is oncogenic both in vitro and in vivo and ALK kinase inhibitors are quite effective in pre-clinical model systems. More recently ALK inhibitors have entered clinical development and remarkably clinical efficacy has been observed in NSCLC patients harbouring EML4-ALK translocations. This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20418096      PMCID： PMC2888755          DOI： 10.1016/j.ejca.2010.04.002

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  42 in total

1.  EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Authors:  Jussi P Koivunen; Craig Mermel; Kreshnik Zejnullahu; Carly Murphy; Eugene Lifshits; Alison J Holmes; Hwan Geun Choi; Jhingook Kim; Derek Chiang; Roman Thomas; Jinseon Lee; William G Richards; David J Sugarbaker; Christopher Ducko; Neal Lindeman; J Paul Marcoux; Jeffrey A Engelman; Nathanael S Gray; Charles Lee; Matthew Meyerson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

2.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Authors:  Ultan McDermott; A John Iafrate; Nathanael S Gray; Toshi Shioda; Marie Classon; Shyamala Maheswaran; Wenjun Zhou; Hwan Geun Choi; Shannon L Smith; Lori Dowell; Lindsey E Ulkus; Georgiana Kuhlmann; Patricia Greninger; James G Christensen; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 3.  Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

Authors:  David A Eberhard; Giuseppe Giaccone; Bruce E Johnson
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

4.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

Authors:  Young Lim Choi; Kengo Takeuchi; Manabu Soda; Kentaro Inamura; Yuki Togashi; Satoko Hatano; Munehiro Enomoto; Toru Hamada; Hidenori Haruta; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Toshihide Ueno; Shuji Takada; Yoshihiro Yamashita; Yukihiko Sugiyama; Yuichi Ishikawa; Hiroyuki Mano
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

5.  Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

Authors:  Kengo Takeuchi; Young Lim Choi; Manabu Soda; Kentaro Inamura; Yuki Togashi; Satoko Hatano; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Yuichi Ishikawa; Hiroyuki Mano
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

6.  A mouse model for EML4-ALK-positive lung cancer.

Authors:  Manabu Soda; Shuji Takada; Kengo Takeuchi; Young Lim Choi; Munehiro Enomoto; Toshihide Ueno; Hidenori Haruta; Toru Hamada; Yoshihiro Yamashita; Yuichi Ishikawa; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

7.  EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.

Authors:  Kazuya Shinmura; Shinji Kageyama; Hong Tao; Tomoyasu Bunai; Masaya Suzuki; Takaharu Kamo; Kazuya Takamochi; Kazuya Suzuki; Masayuki Tanahashi; Hiroshi Niwa; Hiroshi Ogawa; Haruhiko Sugimura
Journal:  Lung Cancer       Date:  2008-02-01       Impact factor: 5.705

8.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Authors:  James G Christensen; Helen Y Zou; Maria E Arango; Qiuhua Li; Joseph H Lee; Scott R McDonnell; Shinji Yamazaki; Gordon R Alton; Barbara Mroczkowski; Gerrit Los
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

9.  EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers.

Authors:  Y Fukuyoshi; H Inoue; Y Kita; T Utsunomiya; T Ishida; M Mori
Journal:  Br J Cancer       Date:  2008-04-15       Impact factor: 7.640

10.  Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.

Authors:  J P Koivunen; J Kim; J Lee; A M Rogers; J O Park; X Zhao; K Naoki; I Okamoto; K Nakagawa; B Y Yeap; M Meyerson; K-K Wong; W G Richards; D J Sugarbaker; B E Johnson; P A Jänne
Journal:  Br J Cancer       Date:  2008-07-01       Impact factor: 7.640
View more
  176 in total

1.  ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Authors:  Johannes M Heuckmann; Michael Hölzel; Martin L Sos; Stefanie Heynck; Hyatt Balke-Want; Mirjam Koker; Martin Peifer; Jonathan Weiss; Christine M Lovly; Christian Grütter; Daniel Rauh; William Pao; Roman K Thomas
Journal:  Clin Cancer Res       Date:  2011-09-26       Impact factor: 12.531

2.  Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.

Authors:  Shuting Ding; Nan Liu; Huanyu Zhao; Guiyang Jiang; Xiupeng Zhang; Enhua Wang
Journal:  Tumour Biol       Date:  2016-02-17

Review 3.  Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.

Authors:  Christine Khoo; Toni-Maree Rogers; Andrew Fellowes; Anthony Bell; Stephen Fox
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 4.  The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.

Authors:  Rathi N Pillai; Suresh S Ramalingam
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 5.  New strategies for treatment of ALK-rearranged non-small cell lung cancers.

Authors:  Takaaki Sasaki; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2011-10-18       Impact factor: 12.531

Review 6.  Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

Authors:  Thierry Berghmans; Myriam Remmelink; Ahmad Awada
Journal:  Lung Cancer (Auckl)       Date:  2012-12-17

Review 7.  Lung cancer as a paradigm for precision oncology in solid tumours.

Authors:  Simon Schallenberg; Sabine Merkelbach-Bruse; Reinhard Buettner
Journal:  Virchows Arch       Date:  2017-07-20       Impact factor: 4.064

Review 8.  ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

Authors:  Christian Rolfo; Francesco Passiglia; Marta Castiglia; Luis E Raez; Paul Germonpre; Ignacio Gil-Bazo; Karen Zwaenepoel; Annemieke De Wilde; Giuseppe Bronte; Antonio Russo; Jan P Van Meerbeeck; Paul Van Schil; Patrick Pauwels
Journal:  Transl Lung Cancer Res       Date:  2014-08

Review 9.  The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.

Authors:  Min Yuan; Li-Li Huang; Jian-Hua Chen; Jie Wu; Qing Xu
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 10.  ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Authors:  Francesca Casaluce; Assunta Sgambato; Paolo Maione; Antonio Rossi; Carmine Ferrara; Alba Napolitano; Giovanni Palazzolo; Fortunato Ciardiello; Cesare Gridelli
Journal:  Target Oncol       Date:  2013-01-17       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.